Pozen, Inc. (POZN) – Bull of the Day
Source: http://www.zacks.com/commentary/12378/Pozen%2C+Inc.+%28POZN%29+-+Bull+of+the+DayPosted on Monday, October 12th, 2009 | In Investing Lessons, Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
Pozen, Inc. (POZN) is one of our top-picks for small-cap biotech. We see the fundamentals as strong and the valuation as low. We are pleased to see the NDA for Vimovo (PN-400) filed and now accepted by the U.S. FDA. FDA acceptance earned Pozen a $10 million milestone from AstraZeneca in August.
We expect sales of Treximet to ramp in the coming quarters now that the groundwork has been laid. And finally, phase III trials on the very exciting PA program should start in the fall.
The company is financially well positioned and fundamentally strong with respect to the pipeline. We recommend being buyers at this level.Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Patni Exceeds Estimates - Analyst Blog - November 24th, 2009
- Nordstrom's North Carolina Debut - Analyst Blog - November 24th, 2009
- JPMorgan Fortifies China Mgmt - Analyst Blog - November 24th, 2009
- Turkcell Misses Estimates - Analyst Blog - November 24th, 2009
- Disappointing Forecast at Intuit - Analyst Blog - November 24th, 2009
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.